Posted by Michael Wonder on 08 Jun 2017
Novartis’s next challenge: pricing breakthrough cancer treatment
8 June 2017 - Swiss drugmaker mulls linking cost to results in each patient.
Novartis, set to beat Kite Pharma to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.
The U.S. FDA is likely to rule in early October on the experimental treatment called CTL019, Vas Narasimhan, global head of drug development and chief medical officer at Novartis, said in an interview. The regulator is due to decide on Kite’s product, designed for a different type of blood cancer, by 29 November.
